β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity

scientific article published on 31 March 2015

β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1210/JC.2014-4009
P932PMC publication ID4454808
P698PubMed publication ID25825945

P2093author name stringDavid A D'Alessio
Benedikt A Aulinger
Torsten P Vahl
Ron L Prigeon
Hilary E Wilson-Pérez
P2860cites workPharmacology, physiology, and mechanisms of incretin hormone actionQ27021545
Use and abuse of HOMA modelingQ28263292
Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men.Q33518270
The glucagon-like peptidesQ33799839
Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humansQ33845996
Effect of endogenous GLP-1 on insulin secretion in type 2 diabetesQ33869732
What if gut hormones aren't really hormones: DPP-4 inhibition and local action of GLP-1 in the gastrointestinal tractQ35110830
Quantitative study of insulin secretion and clearance in normal and obese subjectsQ35809498
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitusQ35824086
Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms.Q36116849
Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance testQ36339659
Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestionQ37061286
Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboonsQ37351161
GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in ratsQ37510130
Genetic variants affecting incretin sensitivity and incretin secretionQ37780493
GLP-1 effects on islets: hormonal, neuronal, or paracrine?Q38123791
The incretin concept todayQ39227026
The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjectsQ42436041
Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects.Q43089866
GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curveQ43664555
Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjectsQ44495085
Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearanceQ44831737
A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretionQ46070008
The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men.Q46087573
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitorsQ46368613
Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockadeQ46515607
Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patientsQ46830628
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.Q51363927
Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function.Q51598262
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.Q51599426
Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.Q52522147
Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.Q53667369
Roles of insulin resistance and obesity in regulation of plasma insulin concentrations.Q54059471
Reduced incretin effect in type 2 (non-insulin-dependent) diabetesQ68865252
Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39Q77804907
P433issue6
P407language of work or nameEnglishQ1860
P304page(s)2489-2496
P577publication date2015-03-31
P1433published inThe Journal of Clinical Endocrinology and MetabolismQ3186902
P1476titleβ-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity
P478volume100

Reverse relations

cites work (P2860)
Q48190910Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients
Q39047697Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.
Q41692104Glucagon-like peptide-1 receptor agonist exendin-4 protects against interleukin-1β-mediated inhibition of glucose-stimulated insulin secretion by mouse insulinoma β cells
Q61456228Identification, pathophysiology, and clinical implications of primary insulin hypersecretion in nondiabetic adults and adolescents
Q26749196Is GLP-1 a hormone: Whether and When?
Q28070256Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review
Q61807256The effect of DPP-4-protected GLP-1 (7-36) on coronary microvascular function in obese adults
Q36902183The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?

Search more.